TSXV:QPT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Quest PharmaTech Inc., a biotechnology company, develops and commercializes antibody based immunotherapeutic products for cancer. More Details


Snowflake Analysis

Flawless balance sheet and fair value.

Share Price & News

How has Quest PharmaTech's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: QPT is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 20% a week.

Volatility Over Time: QPT's weekly volatility has decreased from 36% to 20% over the past year, but is still higher than 75% of Canadian stocks.


Market Performance


7 Day Return

24.1%

QPT

0.3%

CA Biotechs

2.5%

CA Market


1 Year Return

63.6%

QPT

76.8%

CA Biotechs

-0.5%

CA Market

Return vs Industry: QPT underperformed the Canadian Biotechs industry which returned 76.8% over the past year.

Return vs Market: QPT exceeded the Canadian Market which returned -0.5% over the past year.


Shareholder returns

QPTIndustryMarket
7 Day24.1%0.3%2.5%
30 Day24.1%21.1%9.3%
90 Day20.0%24.3%5.6%
1 Year63.6%63.6%76.8%76.8%3.1%-0.5%
3 Year63.6%63.6%12.9%12.9%12.8%1.9%
5 Year157.1%157.1%-1.9%-1.9%47.5%24.9%

Long-Term Price Volatility Vs. Market

How volatile is Quest PharmaTech's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Quest PharmaTech undervalued compared to its fair value and its price relative to the market?

0.29x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate QPT's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate QPT's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: QPT is good value based on its PE Ratio (0.3x) compared to the XN Biotechs industry average (25.3x).

PE vs Market: QPT is good value based on its PE Ratio (0.3x) compared to the Canadian market (15.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate QPT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: QPT is good value based on its PB Ratio (0.3x) compared to the CA Biotechs industry average (6.2x).


Next Steps

Future Growth

How is Quest PharmaTech forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

19.1%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Quest PharmaTech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Quest PharmaTech performed over the past 5 years?

74.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: QPT has a large one-off gain of CA$114.1M impacting its July 31 2020 financial results.

Growing Profit Margin: QPT became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: QPT has become profitable over the past 5 years, growing earnings by 74.6% per year.

Accelerating Growth: QPT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: QPT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.8%).


Return on Equity

High ROE: QPT's Return on Equity (93.3%) is considered outstanding.


Next Steps

Financial Health

How is Quest PharmaTech's financial position?


Financial Position Analysis

Short Term Liabilities: QPT's short term assets (CA$94.5K) exceed its short term liabilities (CA$1.3K).

Long Term Liabilities: QPT's short term assets (CA$94.5K) exceed its long term liabilities (CA$73.7K).


Debt to Equity History and Analysis

Debt Level: QPT is debt free.

Reducing Debt: QPT currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: QPT has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: QPT has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Quest PharmaTech current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate QPT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate QPT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if QPT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if QPT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of QPT's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

15.8yrs

Average management tenure


CEO

Madi Madiyalakan

14.25yrs

Tenure

CA$105,188

Compensation

Dr. Ragupathy Madiyalakan, Ph.D., also known as Madi, has been the Chief Executive Officer of Quest PharmaTech, Inc. since August 2006. Dr. Madiyalakan serves as the President of BioStrat Inc. He founded a...


CEO Compensation Analysis

Compensation vs Market: Madi's total compensation ($USD0.00) is below average for companies of similar size in the Canadian market ($USD166.12K).

Compensation vs Earnings: Madi's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Ragupathy Madiyalakan
CEO & Director14.25yrsCA$105.19k1.61%
CA$ 485.4k
Pierre Vermette
Chief Financial Officer15.83yrsCA$76.35k1.06%
CA$ 321.4k
Thomas Woo
Vice President of Product Development18.42yrsCA$15.00k0.30%
CA$ 90.2k
Roger Andrews
Head of Investor Relations & Corporate Communicationsno datano datano data
Douglas Bachman
Vice President of Corporate Developmentno dataCA$37.94kno data

15.8yrs

Average Tenure

Experienced Management: QPT's management team is seasoned and experienced (15.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ragupathy Madiyalakan
CEO & Director14.25yrsCA$105.19k1.61%
CA$ 485.4k
Bin Huang
Director0.58yrCA$4.50k0.012%
CA$ 3.6k
William Meekison
Independent Director3yrsCA$25.00k0.0060%
CA$ 1.8k
Ki-Jun Hwang
Member of Scientific Advisory Board15.25yrsno datano data
Ronald Moore
Member of Scientific Advisory Board15.25yrsno datano data
Christopher Nicodemus
Chairman of Scientific Advisory Board10.33yrsno datano data
Shawn Lu
Independent Director5yrsCA$25.00kno data
Michael Hollingsworth
Member of Scientific Advisory Boardno datano datano data

10.3yrs

Average Tenure

55yo

Average Age

Experienced Board: QPT's board of directors are seasoned and experienced ( 10.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Quest PharmaTech Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Quest PharmaTech Inc.
  • Ticker: QPT
  • Exchange: TSXV
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$30.195m
  • Shares outstanding: 167.75m
  • Website: https://www.questpharmatech.com

Location

  • Quest PharmaTech Inc.
  • 8123 Roper Road NW
  • Edmonton
  • Alberta
  • T6E 6S4
  • Canada

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
QPTTSXV (TSX Venture Exchange)YesCommon SharesCACADMar 1999
QPTF.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDMar 1999

Biography

Quest PharmaTech Inc., a biotechnology company, develops and commercializes antibody based immunotherapeutic products for cancer. The company focuses on combinatorial immunotherapeutic approaches to cancer...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/26 23:04
End of Day Share Price2020/11/25 00:00
Earnings2020/07/31
Annual Earnings2020/01/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.